Project leader
ST MicroeletronicsPartners
France Telecom (Orange Labs), ELA Medical, SORIN Group, OPEN PLUG, MOBILE GOV, NEURELEC, LEAT - Université Nice Sophia Antipolis, I3S - Université Nice Sophia AntipolisFunders
FUI,STM3
Solution for Treatment and Monitoring in Mobile Medicine.
The main objective of mobile medicine is to allow the follow-up of a patient in his home, through a chain of information collection from sensors (or implants) that the patient carries on him. These sensors transmit their information to a subsystem (SD card) which allows them to be collected, filtered and then reassembled (via a mobile phone) to dedicated servers and associated services enabling health professionals to monitor their remote patients and react in real time when necessary.Some technical solutions have been developed to date, which generally rely on proprietary systems, and which in their entirety do not address (or little) security issues and respect for the privacy of patients.
The STM3 program aims first and foremost to secure this communication channel. We can mention the impact on the main links of this chain:
– For sensors or implants: avoid clones, pair them with the SD card in the phone, protect the radio frequency communication (data confidentiality), guarantee any remote reconfigurations.
– For the SD card: Authenticate after servers at the end of the chain, ensure the integrity and authenticity of embedded data processing software, ergonomically interact with the user via the screen and keypad of the phone.
– For servers and health professionals, to be able to ensure access rights and protect the confidentiality and integrity of the exchanges.
The second objective of the STM3 project is to integrate the whole chain on standard hardware elements (mobile phone) and on consumer-type technologies (MicroSD card) to optimize the cost of the hardware solution compared to proprietary approaches.
In the framework of the STM3 project, the aim is to prove the feasibility and adequacy of the studied solutions by developing a demonstrator of the global chain. The industrial partners then intend to value each one in their field the selected technologies, to put on the market offers significantly improving the cost and the quality of the medical follow-up at home.